Prediction of Overall Survival of Patients with Completely Resected Non-Small Cell Lung Cancer: Analyses of Preoperative Spirometry, Preoperative Blood Tests, and Other Clinicopathological Data

References

• Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2 ):87–108. doi:10.3322/caac.2126225651787
   PubMed Web of Science ®Google Scholar
• Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2 ):115–132. doi:10.3322/caac.2133826808342
   PubMed Web of Science ®Google Scholar
• Goldstraw P, Crowley J, Chansky K, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol. 2007;2(8 ):706–714. doi:10.1097/JTO.0b013e31812f3c1a17762336
   PubMed Web of Science ®Google Scholar
• Hanna N, Johnson D, Temin S, et al. Systemic therapy for stage IV non-small-cell lung cancer: American Society Of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2017;35(30 ):3484–3515. doi:10.1200/JCO.2017.74.606528806116
   PubMed Web of Science ®Google Scholar
• Rinaldi S, Berardi R. Lung cancer prognosis: can histological patterns and morphological features have a role in the management of lung cancer patients? Ann Transl Med. 2017;5(17 ):353. doi:10.21037/atm28936447
   PubMed Web of Science ®Google Scholar
• Tamura T, Kurishima K, Nakazawa K, Ishikawa H, Satoh H, Hizawa N. Similar survival benefits of a good response and stable disease to platinum-based chemotherapy in non-small cell lung cancer. Oncol Lett. 2015;10(2 ):1135–1140. doi:10.3892/ol.2015.335026622639
   PubMed Web of Science ®Google Scholar
• Sanz Rubiales A, Del Valle Rivero ML, Fiorini Talavera AB, Fernandez Gonzalez M. Platinum derivatives alone, a reasonable option to treat locally advanced non-small cell lung cancer with chemo-radiotherapy. Lung Cancer. 2015;89(1 ):84–85. doi:10.1016/j.lungcan.2015.04.01325982010
   PubMed Web of Science ®Google Scholar
• Matsuzaki A, Hashimoto N, Okachi S, et al. Clinical impact of the lower limit of normal of FEV1/FVC on survival in lung cancer patients undergoing thoracic surgery. Respir Investig. 2016;54(3 ):184–192. doi:10.1016/j.resinv.2015.11.006
   PubMedGoogle Scholar
• Ferguson MK, Dignam JJ, Siddique J, Vigneswaran WT, Celauro AD. Diffusing capacity predicts long-term survival after lung resection for cancer. Eur J Cardiothorac Surg. 2012;41(5 ):e81–e86. doi:10.1093/ejcts/ezs04922368187
   PubMed Web of Science ®Google Scholar
• McMillan DC. The systemic inflammation-based Glasgow Prognostic Score: a decade of experience in patients with cancer. Cancer Treat Rev. 2013;39(5 ):534–540. doi:10.1016/j.ctrv.2012.08.00322995477
   PubMed Web of Science ®Google Scholar
• Ding N, Pang Z, Shen H, Ni Y, Du J, Liu Q. The prognostic value of PLR in lung cancer, a meta-analysis based on results from a large consecutive cohort. Sci Rep. 2016;6:34823. doi:10.1038/srep3482327703265
   PubMed Web of Science ®Google Scholar
• Kawachi R, Nakazato Y, Takei H, Koshi-ishi Y, Goya T. Clinical significance of preoperative carcinoembryonic antigen level for clinical stage I non-small cell lung cancer: can preoperative carcinoembryonic antigen level predict pathological stage? Interact Cardiovasc Thorac Surg. 2009;9(2 ):199–202. doi:10.1510/icvts.2009.20669819457896
   PubMedGoogle Scholar
• Maeda R, Suda T, Hachimaru A, Tochii D, Tochii S, Takagi Y. Clinical significance of preoperative carcinoembryonic antigen level in patients with clinical stage IA non-small cell lung cancer. J Thorac Dis. 2017;9(1 ):176–186. doi:10.21037/jtd28203421
   PubMed Web of Science ®Google Scholar
• Pan YW, Zhou ZG, Wang M, et al. Combination of IL-6, IL-10, and MCP-1 with traditional serum tumor markers in lung cancer diagnosis and prognosis. Genet Mol Res. 2016;15(4 ). doi:10.4238/gmr15048949.
   Google Scholar
• Shimosato Y. [Histological typing of lung and pleural tumors (3rd edition, 1999): malignant epithelial tumors]. Nihon Rinsho. 2002;60(Suppl 5 ):123–131.
   PubMedGoogle Scholar
• Amin MB, Greene FL, Edge SB, et al. The eighth edition AJCC cancer staging manual: continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. CA Cancer J Clin. 2017;67(2 ):93–99. doi:10.3322/caac.2138828094848
   PubMed Web of Science ®Google Scholar
• Travis WD, Brambilla E, Burke AP, Marx A, Nicholson AG. Introduction to the 2015 world health organization classification of tumors of the lung, pleura, thymus, and heart. J Thorac Oncol. 2015;10(9 ):1240–1242. doi:10.1097/JTO.000000000000066326291007
   PubMed Web of Science ®Google Scholar
• Harrell FE Jr., Califf RM, Pryor DB, Lee KL, Rosati RA. Evaluating the yield of medical tests. JAMA. 1982;247(18 ):2543–2546. doi:10.1001/jama.1982.033204300470307069920
   PubMed Web of Science ®Google Scholar
• Kang L, Chen W, Petrick NA, Gallas BD. Comparing two correlated C indices with right-censored survival outcome: a one-shot nonparametric approach. Stat Med. 2015;34(4 ):685–703. doi:10.1002/sim.637025399736
   PubMed Web of Science ®Google Scholar
• Yamauchi Y, Muley T, Safi S, et al. The dynamic pattern of recurrence in curatively resected non-small cell lung cancer patients: experiences at a single institution. Lung Cancer. 2015;90(2 ):224–229. doi:10.1016/j.lungcan.2015.09.01026415991
   PubMed Web of Science ®Google Scholar
• Yamashita T, Uramoto H, Onitsuka T, et al. Association between lymphangiogenesis-/micrometastasis- and adhesion-related molecules in resected stage I NSCLC. Lung Cancer. 2010;70(3 ):320–328. doi:10.1016/j.lungcan.2010.02.01320363046
   PubMed Web of Science ®Google Scholar
• Paleiron N, Bylicki O, Andre M, et al. Targeted therapy for localized non-small-cell lung cancer: a review. Onco Targets Ther. 2016;9:4099–4104. doi:10.2147/OTT.S10493827462164
   PubMed Web of Science ®Google Scholar
• al-Kattan K, Sepsas E, Fountain SW, Townsend ER. Disease recurrence after resection for stage I lung cancer. Eur J Cardiothorac Surg. 1997;12(3 ):380–384. doi:10.1016/S1010-7940(97)00198-X9332915
   PubMed Web of Science ®Google Scholar
• Pollack JR. A perspective on DNA microarrays in pathology research and practice. Am J Pathol. 2007;171(2 ):375–385. doi:10.2353/ajpath.2007.07034217600117
   PubMed Web of Science ®Google Scholar
• Dehing-Oberije C, Aerts H, Yu S, et al. Development and validation of a prognostic model using blood biomarker information for prediction of survival of non-small-cell lung cancer patients treated with combined chemotherapy and radiation or radiotherapy alone (NCT00181519, NCT00573040, and NCT00572325). Int J Radiat Oncol Biol Phys. 2011;81(2 ):360–368. doi:10.1016/j.ijrobp.2010.06.01120888135
   PubMed Web of Science ®Google Scholar
• Deng M, Ma X, Liang X, Zhu C, Wang M. Are pretreatment neutrophil-lymphocyte ratio and platelet-lymphocyte ratio useful in predicting the outcomes of patients with small-cell lung cancer? Oncotarget. 2017;8(23 ):37200–37207. doi:10.18632/oncotarget.1655328380461
   PubMedGoogle Scholar
• Drummond MB, Hansel NN, Connett JE, Scanlon PD, Tashkin DP, Wise RA. Spirometric predictors of lung function decline and mortality in early chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012;185(12 ):1301–1306. doi:10.1164/rccm.201202-0223OC22561963
   PubMed Web of Science ®Google Scholar
• Fry JS, Hamling JS, Lee PN. Systematic review with meta-analysis of the epidemiological evidence relating FEV1 decline to lung cancer risk. BMC Cancer. 2012;12:498. doi:10.1186/1471-2407-12-49823101666
   PubMed Web of Science ®Google Scholar
• de-Torres JP, Marin JM, Casanova C, et al. Identification of COPD patients at high risk for lung cancer mortality using the COPD-LUCSS-DLCO. Chest. 2016;149(4 ):936–942. doi:10.1378/chest.15-186826513409
   PubMed Web of Science ®Google Scholar
• Liptay MJ, Basu S, Hoaglin MC, et al. Diffusion lung capacity for carbon monoxide (DLCO) is an independent prognostic factor for long-term survival after curative lung resection for cancer. J Surg Oncol. 2009;100(8 ):703–707. doi:10.1002/(ISSN)1096-909819798693
   PubMed Web of Science ®Google Scholar
• Wang J, Olak J, Ferguson MK. Diffusing capacity predicts operative mortality but not long-term survival after resection for lung cancer. J Thorac Cardiovasc Surg. 1999;117(3 ):581–586; discussion 586–587. doi:10.1016/S0022-5223(99)70338-7
   Web of Science ®Google Scholar
• Koh CH, Bhoo-Pathy N, Ng KL, et al. Utility of pre-treatment neutrophil-lymphocyte ratio and platelet-lymphocyte ratio as prognostic factors in breast cancer. Br J Cancer. 2015;113(1 ):150–158. doi:10.1038/bjc.2015.18326022929
   PubMed Web of Science ®Google Scholar
• Proctor MJ, Morrison DS, Talwar D, et al. An inflammation-based prognostic score (mGPS) predicts cancer survival independent of tumour site: a glasgow inflammation outcome study. Br J Cancer. 2011;104(4 ):726–734. doi:10.1038/sj.bjc.660608721266974
   PubMed Web of Science ®Google Scholar
• Kinoshita A, Onoda H, Imai N, et al. The glasgow prognostic score, an inflammation based prognostic score, predicts survival in patients with hepatocellular carcinoma. BMC Cancer. 2013;13:52. doi:10.1186/1471-2407-13-5223374755
   PubMed Web of Science ®Google Scholar
• Petrelli F, Barni S, Coinu A, et al. The modified glasgow prognostic score and survival in colorectal cancer: a pooled analysis of the literature. Rev Recent Clin Trials. 2015;10(2 ):135–141. doi:10.2174/157488711066615031712141325778832
   PubMedGoogle Scholar
• Zhang H, Xia H, Zhang L, Zhang B, Yue D, Wang C. Clinical significance of preoperative neutrophil-lymphocyte vs platelet-lymphocyte ratio in primary operable patients with non-small cell lung cancer. Am J Surg. 2015;210(3 ):526–535. doi:10.1016/j.amjsurg.2015.03.02226105800
   PubMed Web of Science ®Google Scholar
• Bambace NM, Holmes CE. The platelet contribution to cancer progression. J Thromb Haemost. 2011;9(2 ):237–249. doi:10.1111/j.1538-7836.2010.04131.x21040448
   PubMed Web of Science ®Google Scholar
• Sharma D, Brummel-Ziedins KE, Bouchard BA, Holmes CE. Platelets in tumor progression: a host factor that offers multiple potential targets in the treatment of cancer. J Cell Physiol. 2014;229(8 ):1005–1015. doi:10.1002/jcp.v229.824374897
   PubMed Web of Science ®Google Scholar
• Jurasz P, Alonso-Escolano D, Radomski MW. Platelet–cancer interactions: mechanisms and pharmacology of tumour cell-induced platelet aggregation. Br J Pharmacol. 2004;143(7 ):819–826. doi:10.1038/sj.bjp.070601315492016
   PubMed Web of Science ®Google Scholar
• Fiala O, Pesek M, Finek J, et al. Prognostic significance of serum tumor markers in patients with advanced-stage NSCLC treated with pemetrexed-based chemotherapy. Anticancer Res. 2016;36(1 ):461–466.26722082
   PubMed Web of Science ®Google Scholar
• Zhang ZH, Han YW, Liang H, Wang LM. Prognostic value of serum CYFRA21-1 and CEA for non-small-cell lung cancer. Cancer Med. 2015;4(11 ):1633–1638. doi:10.1002/cam4.49326333429
   PubMed Web of Science ®Google Scholar
• Chen F, Yan CE, Li J, Han XH, Wang H, Qi J. Diagnostic value of CYFRA 21-1 and CEA for predicting lymph node metastasis in operable lung cancer. Int J Clin Exp Med. 2015;8(6 ):9820–9824.26309663
   PubMed Web of Science ®Google Scholar